调节和氧化应激在治疗性结肠炎的肠粘膜
Na Yu1,2, Jingwen Xu3, Jie Fan1
1Department of Geriatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
International journal of pharmaceutics: X
|November 17, 2025
概括
这项研究引入了一种新的化颗粒 (MgH2@MgO) 用于性结肠炎 (UC) 治疗. 该粒子安全地释放气,有效地减少UC的炎症和氧化应激.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 涉及由活性氧物种 (ROS) 驱动的慢性肠炎症.
- 目前的UC治疗有局限性,包括显著的不良副作用和长期毒性问题.
- 因其抗氧化特性和膜透性而成为UC的有希望的,无毒的治疗剂.
研究的目的:
- 开发一种新的,安全的气输送系统,用于UC治疗.
- 评估化颗粒 (MgH2@MgO) 在管理UC中的有效性.
- 调查MgH2@MgO在缓解UC进展中的潜在机制.
主要方法:
- 合成一种新型MgH2颗粒,封装在一个MgO外 (MgH2@MgO) 中,用于控制释放.
- 在体外和体内评估MgH2@MgO吸收ROS的能力.
- 在UC模型中评估MgH2@MgO的抗炎作用和对NF-κB信号通路的影响.
主要成果:
- MgH2@MgO颗粒证明了有效和可控的释放.
- MgH2@MgO成功地清除了过度的ROS,这是结直肠损伤的关键因素.
- 用MgH2@MgO治疗显著减少了肠道炎症,并通过抑制NF-κB通路逆转了UC进展.
结论:
- MgH2@MgO颗粒代表了一种安全有效的气输送策略,用于打击UC.
- 这种新材料显示了在性结肠炎的预防和治疗中临床应用的潜力.
- 这项研究提供了强有力的实验证据,支持用于炎症性肠道疾病的基于的疗法.
相关概念视频
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Peptic Ulcer Disease IV: Management
419
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
419
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
622
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


